⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5719204 | 0.67 | — | — | |
| SCHEMBL47739 | 0.67 | — | — | |
| SCHEMBL1006702 | 0.67 | — | — | |
| SCHEMBL4162328 | 0.63 | ALDH1A1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL27782124 | 0.63 | — | — | |
| SCHEMBL27952649 | 0.63 | — | — | |
| SCHEMBL27750855 | 0.63 | — | — | |
| SCHEMBL18641296 | 0.63 | — | — | |
| SCHEMBL3666143 | 0.59 | — | — | |
| SCHEMBL4119428 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | claimed |
| CN-110520434-A | The method for preparing arylalkoxysilicane by dehydrogenation silylation | DOW SILICONES CORP | 2019-11-29 | — | — | CN | claimed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | claimed |
| CN-109735925-A | Easy dyeing and the polyester of degradation FDY and preparation method thereof | 江苏恒力化纤股份有限公司 | 2019-05-10 | — | — | CN | claimed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | claimed |
| EP-3153501-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | claimed |
| US-10076504-B2 | Glucagon antagonists | LIGAND PHARMACEUTICALS, INC. | 2018-09-18 | — | — | US | claimed |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-01-25 | — | — | US | claimed |
| US-9783494-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2017-10-10 | — | — | US | claimed |
| CN-101610995-B | Glucagon receptor antagonists | 症变治疗公司 | 2017-08-08 | — | — | CN | claimed |
| US-8710236-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2014-04-29 | — | — | US | claimed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | claimed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | claimed |
| EP-1730131-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-05-09 | — | — | EP | claimed |
| CN-101610995-A | Novel glucagon receptor antagonists | METABASIS THERAPEUTICS INC (US) | 2009-12-23 | — | — | CN | claimed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| EP-0977748-B1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-03-26 | — | — | EP | claimed |
| EP-0915837-A1 | GLYOXYLIC ACID DERIVATIVES | BAYER AG (DE) | 1999-05-19 | — | — | EP | claimed |
| WO-1998003474-A1 | GLYOXYLIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-29 | — | — | WO | claimed |